The purpose of the study is observing of the damage of the cardiovascular system in patients with systemic scleroderma (SS). Materials and methods. Clinical research was conducted in  90 patients with a diffuse form of SS, aged 25 to 58 years (average age 39,1±5 years), with an average disease duration of  8.2±6 years, were involved in the study. All patients involved in the study were divided into three groups according to the type of treatment: patients in 1^st  group  (n-42) received conventional treatment according to the recommendations of the standard of care for SS, 2^nd  group (n-48) received treatment according to the standard of care for patients in the 2^nd group(n-38) statin (atorvastatin drug in the amount of 20-40 mg for 6 months) in addition to traditional treatment, tocilizumab (8 mg/kg) according to the scheme (8 mg/kg) dose in the form of injection once every 4 weeks) was prescribed for 6 months. Results. According to the obtained results, when the changes in the systolic and diastolic volume of the left ventricle during the study were studied, the changes in the systolic volume of the left ventricle reliably increased in patients of 1^st  group compared to the beginning of the study, while in 2^nd group, this indicator did not change, which is confirmed by the unreliable change of values in statistical analysis. Also, in the 3^rd  group, it was seen that the heart remodeling was shifted in a positive direction with a reliable decrease in end-systolic volume of left ventricular (ESVLV). Left ventricular fraction (LVF), which is the main gradient determining the functional state of the left ventricle, showed negative results in the 1st group of patients, decreasing in reliable values during our study. In the 2^nd group of patients who received atorvastatin in addition to conventional treatment, this indicator changed unreliable, that is, the values shifted in one direction or another. The thickness of carotid arteries (TCA), which is considered a vascular component of cardiovascular system changes, changed as follows during six months of treatment in our research: in 1^st group, the thickness of IMC showed a worsening of the process even though it was at less reliable (p<0.05) values. In 2^nd group, the values did not change. In patients of 3^rd group  who received atorvastatin and tocilizumab drugs in addition to traditional treatment, the IMC thickness decreased reliably (p<0.01) after treatment and reflected positive results. Conclusion. In patients with SS, negative changes were detected in the cardiovascular system according to the results of ECG and EchoCG examination, in particular, left ventricular hypertrophy - in 46% of cases, coronary insufficiency - in 35%, and the end systolic volume of the left ventricle was found in 51% and increased myocardial mass by 68%. In patients with systemic scleroderma, pathological enlargement of the intima-media complex of the common carotid artery (>0.9 mm) was detected in 35% of cases, atherosclerotic plaques in 21% of patients.

Keywords: systemic sclerosis, cardiovascular system, IL-6, treatment, statins, gene engineering drugs